Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and L-dopa-treated rats

Neurochemical Research

Volumn 31, Issue 11, 2006, Pages 1337-1347

  Ba, Maowen ^a   Kong, Min ^a   Yang, Hongqi ^a   Ma, Guozhao ^b   Lu, Guoqiang ^a   Chen, Shengdi ^a   Liu, Zhenguo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

CaMKII; GluR1; L dopa; Parvalbumin; PD; Phosphorylation

Indexed keywords

AMPA RECEPTOR; APOMORPHINE; BENSERAZIDE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR 1; LEVODOPA METHYL ESTER; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OXIDOPAMINE; PARVALBUMIN; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE INHIBITOR; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; FEMALE; MOTOR PERFORMANCE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; BENZYLAMINES; BLOTTING, WESTERN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; ENZYME INHIBITORS; FEMALE; IMMUNOHISTOCHEMISTRY; LEVODOPA; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; STEREOTYPED BEHAVIOR; SUBCELLULAR FRACTIONS; SULFONAMIDES; SYMPATHOLYTICS;

EID: 33751305122     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9177-9     Document Type: Article

References (44)

1. Standaert DG, Stern MB (1993) Update on the management of Parkinson's disease. Med Clin N Am 77:169-183
2. Chase TN, Oh JD (2000) Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications. Ann Neurol 47:S122-S129
3. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW (2000) The evolution and origin of motor complications in Parkinson's disease. Neurology 55:S13-S20
4. Greenamyre JT (2000) New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. Neurology 15:67-80
5. Nakanishi S, Nakajima Y, Masu M, Ueda Y, Nakahara K, Watanabe D, Yamaguchi S, Kawabata S, Okada M (1998) Glutamate receptors: brain function and signal transduction. Brain Res Rev 26:230-235
6. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595
7. Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E (2000) Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse 36:267-274
8. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578
9. Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23:133-139
10. 2+/calmodulin-dependent protein kinase II regulatory phosphorylation site in the amino-3-hydroxyl-5-methyl-4-isoxazole-propionate type gluatamate receptor. J Biol Chem 272:32727-32730
11. Mammen AL, Kameyame K, Roche KW, Huganir RL (1997) Phosphorylation of the amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. J Biol Chem 272:32528-32533
12. Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179-1188
13. Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (2000) Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20:89-102
14. Benke TA, Luthi A, Isaac JT, Collingridge GL (1998) Modulation of AMPA receptor unitary conductance by synaptic activity. Nature 393:793-797
15. Brocke L, Chiang LW, Wagner PD, Schulman H (1999). Functional implications of the subunit composition of neuronal CaM kinase II. J Biol Chem 274:22713-22722
16. 2+/calmodulin-dependent protein kinase type II and the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (ampa) receptor in response to a threonine-devoid diet. Neuroscience 126:1053-1062
17. Oh JD, Vaughan CL, Chase TN (1999) Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res 821:433-442
18. Tallaksen-Greene SJ, Wiley RG, Albin RL (1992) Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res 594:165-170
19. Tallaksen-Greene SJ, Albin RL (1994) Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience 61:509-519
20. Chen Q, Veenman CL, Reiner A (1996) Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 73:715-731
21. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004) NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 47:184-194
22. Brown AM, Deutch AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Eur J Neurosci 22:247-256
23. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press
24. Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74
25. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132
26. Anderson KD, Reiner A (1990) Extensive co-occurrence of substance P and dynorphin in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization. J Comp Neurol 295:339-369
27. Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15:133-139
28. Reiner A, Anderson KD (1990) The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings. Brain Res Rev 15:251-265
29. DiFiglia M (1987) Synaptic organization of cholinergic neurons in the monkey neostriatum. J Comp Neurol 255:245-258
30. Cowan RL, Wilson CJ, Emson PC, Heizmann CW (1990) Parvalbumin-containing GABAergic interneurons in the rat neostriatum. J Comp Neurol 302:197-205
31. Figueredo-Cardenas G, Chen Q, Reiner A (1997) Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorasecontaining interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp Neurol 146:444-457
32. Dunah AW, Standaert DG (2001) Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J Neurosci 21: 5546-5558
33. Kwok KHH, Tse YC, Wong RNS, Yung KKL (1997) Cellular localization of GluR1, GluR2/3 and GluR4 glutamate receptor subunits in neurons of the rat neostriatum. Brain Res 778:43-55
34. Bernard V, Somogyi P, Bolam JP (1997) Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. J Neurosci 17:819-833
35. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293
36. Lange KW, Kornhuber J, Riederer P (1997) Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21:393-400
37. Perier C, Marin C, Bonastre M, Tolosa E, Hirsch EC (2002) AMPA receptor antagonist LY293558 reverses preproencephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. Eur J Neurosci 16:2236-2240
38. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN (1995) Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18
39. Bolam JP, Hanley JJ, Booth PAC, Bevan MD(2000) Synaptic organisation of the basal ganglia. J Anat 196:527-542
40. Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25:103-126
41. Lee HK, Takamiya K, Han JS, Man H, Kim CH, Rumbaugh G, Yu S, Ding L, He C, Petralia RS, Wenthold RJ, Gallagher M, Huganir RL (2003) Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 112:631-643
42. Stefani A, Pisani A, Bernardi G, Bonci A, Mercuri NB, Stratta F, Calabresi P (1995) The modulation of dopamine receptors in rat striatum. J Neural Transm 45:61-66
43. Wickens JR, Kotter R, Alexander ME (1995) Effects of local connectivity on striatal function: stimulation and analysis of a model. Synapse 20:281-298
44. Hayashi Y, Ishida A, Katagiri H, Mishina M, Fujisawa H, Manabe T, Takahashi T (1997) Calcium- and calmodulin-dependent phosphorylation of AMPA type glutamate receptor subunits by endogenous protein kinases in the postsynaptic density. Brain Res Mol Brain Res 46:338-342